We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Outlook for 2015: Antitrust Litigation in the Pharma Industry - More Than Just Actavis Progeny

Robert F. Leibenluft

Robert F. Leibenluft,

Washington, D.C.

Lauren E. Battaglia

Lauren E. Battaglia,

Washington, D.C.

Leigh Oliver

20 March 2015
In 2014 there were a number of significant antitrust developments for the pharmaceutical industry. These involved not only challenges with respect to pharmaceutical patent litigation settlements (so-called “reverse payment” agreements), but also investigations and challenges to conduct related to product reformulations, Risk Evaluation and Mitigation Strategies (REMS), and FDA citizen petitioning activity.
Outlook for 2015: Antitrust Litigation in the Pharma Industry - More Than Just Actavis Progeny
Robert F. Leibenluft

Robert F. Leibenluft,

Washington, D.C.

Lauren E. Battaglia

Lauren E. Battaglia,

Washington, D.C.

Leigh Oliver

Loading data